{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T06:40:40Z","timestamp":1784011240703,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100032527","name":"Bernhard-Nocht-Institut f\u00fcr Tropenmedizin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100032527","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Loiasis, caused by the nematode\/filaria\n                      <jats:italic>Loa loa<\/jats:italic>\n                      , presents a major health burden in Central and West Africa. Despite the growing recognition of loiasis\u2019 medical significance, current antifilarial drugs remain inadequate in terms of efficacy and safety, particularly for individuals with hypermicrofilaremia. This systematic review aims to evaluate the efficacy of antifilarial treatment regimens for reducing\n                      <jats:italic>L. loa<\/jats:italic>\n                      microfilaremia and provide guidance on treatment strategies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A systematic review was conducted to evaluate the efficacy of antifilarial treatment regimens on reducing\n                      <jats:italic>L. loa<\/jats:italic>\n                      microfilaremia. Data on the percentage reduction of microfilaremia from baseline to nadir were extracted for each treatment regimen.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 27 studies were included in the review, with treatment regimens involving albendazole (ALB), mebendazole (MBZ), ivermectin (IVM), diethylcarbamazine (DEC), levamisole, imatinib, and moxidectin, among others. ALB and MBZ showed dose- and duration-dependent efficacy, with extended treatment leading to up to a 98\u2013100% microfilaremia reduction. IVM showed a dose-dependent effect, with single doses of 200\u2013400 \u00b5g\/kg reducing microfilaremia by 88\u201392%. DEC exhibited high efficacy, achieving up to a 100% microfilaremia reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Antifilarial drug efficacy against\n                      <jats:italic>L. loa<\/jats:italic>\n                      microfilaremia varies by dosage and treatment duration, with IVM and DEC demonstrating rapid, high efficacy but presenting safety concerns for hypermicrofilaremic individuals. ALB and MBZ show efficacy with extended treatment but are slower acting. Further research is needed to optimize treatment regimens and assess clinical outcomes beyond microfilaremia reduction.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13071-025-07189-w","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T19:06:19Z","timestamp":1765393579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Activity of antifilarial drugs on microfilaremia in the treatment of loiasis: a systematic review"],"prefix":"10.1186","volume":"19","author":[{"given":"Pia","family":"Michelitsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Matthies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Nordmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rella Zoleko","family":"Manego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ramharter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"7189_CR1","unstructured":"CDC. About loiasis. Filarial worms. https:\/\/www.cdc.gov\/filarial-worms\/about\/loiasis.html#:~:text=to%20treat%20loiasis. Accessed 20 Mar 2025."},{"key":"7189_CR2","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1179\/136485906X112194","volume":"100","author":"M Boussinesq","year":"2006","unstructured":"Boussinesq M. Loiasis. Ann Trop Med Parasitol. 2006;100:715\u201331.","journal-title":"Ann Trop Med Parasitol"},{"key":"7189_CR3","unstructured":"CDC. CDC - DPDx - Loiasis. https:\/\/www.cdc.gov\/dpdx\/loiasis\/index.html. Accessed 20 Mar 2025."},{"key":"7189_CR4","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1016\/S1473-3099(23)00438-3","volume":"24","author":"M Ramharter","year":"2024","unstructured":"Ramharter M, Butler J, Mombo-Ngoma G, Nordmann T, Davi SD, Zoleko Manego R. The African eye worm: current understanding of the epidemiology, clinical disease, and treatment of loiasis. Lancet Infect Dis. 2024;24:e165\u201378.","journal-title":"Lancet Infect Dis"},{"key":"7189_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S1473-3099(16)30405-4","volume":"17","author":"CB Chesnais","year":"2017","unstructured":"Chesnais CB, Takougang I, Pagu\u00e9l\u00e9 M, Pion SD, Boussinesq M. Excess mortality associated with loiasis: a retrospective population-based cohort study. Lancet Infect Dis. 2017;17:108\u201316.","journal-title":"Lancet Infect Dis"},{"key":"7189_CR6","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/S1473-3099(20)30256-5","volume":"20","author":"L Veletzky","year":"2020","unstructured":"Veletzky L, Hergeth J, Stelzl DR, Mischlinger J, Manego RZ, Mombo-Ngoma G, et al. Burden of disease in Gabon caused by loiasis: a cross-sectional survey. Lancet Infect Dis. 2020;20:1339\u201346.","journal-title":"Lancet Infect Dis"},{"key":"7189_CR7","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"7189_CR8","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"key":"7189_CR9","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg. 2003;73:712\u20136.","journal-title":"ANZ J Surg"},{"key":"7189_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2020","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Syn Meth. 2021;12:55\u201361.\u00a0https:\/\/doi.org\/10.1002\/jrsm.1411.","journal-title":"Res Syn Meth"},{"key":"7189_CR11","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/0035-9203(87)90156-8","volume":"81","author":"GD Burchard","year":"1987","unstructured":"Burchard GD, Kern P. Failure of high dose mebendazole as a microfilaricide in patients with loiasis. Trans R Soc Trop Med Hyg. 1987;81:420.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"7189_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/cid\/ciab906","volume":"75","author":"JT Campillo","year":"2022","unstructured":"Campillo JT, Bikita P, Hemilembolo M, Louya F, Missamou F, Pion SDS, et al. Safety and efficacy of levamisole in loiasis: a randomized, placebo-controlled, double-blind clinical trial. Clin Infect Dis. 2022;75:19\u201327.","journal-title":"Clin Infect Dis"},{"key":"7189_CR13","first-page":"47","volume":"71","author":"B Carme","year":"1991","unstructured":"Carme B, Ebikili B, Mbitsi A, Copin N. Essai th\u00e9rapeutique de l\u2019ivermectine au cours de la loase \u00e0 moyenne et forte microfilar\u00e9mie [Therapeutic trial with ivermectin in loiasis with medium and high microfilaremia]. Ann Soc Belg Med Trop. 1991;71:47\u201350.","journal-title":"Ann Soc Belg Med Trop"},{"key":"7189_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/00034983.1961.11686047","volume":"55","author":"BO Duke","year":"1961","unstructured":"Duke BO, Moore PJ. A trial of banocide as a means of controlling the transmission of loiasis on a rubber estate in Nigeria. Ann Trop Med Parasitol. 1961;55:263\u201377.","journal-title":"Ann Trop Med Parasitol"},{"key":"7189_CR15","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0035-9203(97)90040-7","volume":"91","author":"TH Duong","year":"1997","unstructured":"Duong TH, Kombila M, Ferrer A, Bureau P, Gaxotte P, Richard-Lenoble D. Reduced Loa loa microfilaria count ten to twelve months after a single dose of ivermectin. Trans R Soc Trop Med Hyg. 1997;91:592\u20133.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"7189_CR16","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/cid\/cix016","volume":"64","author":"JA Herrick","year":"2017","unstructured":"Herrick JA, Legrand F, Gounoue R, Nchinda G, Montavon C, Bopda J, et al. Posttreatment reactions after single-dose diethylcarbamazine or ivermectin in subjects with Loa loa infection. Clin Infect Dis. 2017;64:1017\u201325.","journal-title":"Clin Infect Dis"},{"key":"7189_CR17","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/00034983.1987.11812120","volume":"81","author":"M Van Hoegaerden","year":"1987","unstructured":"Van Hoegaerden M, Ivanoff B, Flocard F, Salle A, Chabaud B. The use of mebendazole in the treatment of filariases due to Loa loa and Mansonella perstans. Ann Trop Med Parasitol. 1987;81:275\u201382.","journal-title":"Ann Trop Med Parasitol"},{"key":"7189_CR18","first-page":"275","volume":"60","author":"J Kamgno","year":"2000","unstructured":"Kamgno J, Gardon J, Boussinesq M. Essai de pr\u00e9vention des enc\u00e9phalopathies \u00e0 Loa loa post-ivermectine par l\u2019administration d\u2019une faible dose initiale [Analysis of the prevention of post-ivermectin Loa loa encephalopathy by administration of initial low dose]. Med Trop. 2000;60:275\u20137.","journal-title":"Med Trop"},{"key":"7189_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1051\/parasite\/200209159","volume":"9","author":"J Kamgno","year":"2002","unstructured":"Kamgno J, Boussinesq M. Effect of a single dose (600 mg) of albendazole on Loa loa microfilaraemia. Parasite. 2002;9:59\u201363.","journal-title":"Parasite"},{"key":"7189_CR20","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.trstmh.2007.03.018","volume":"101","author":"J Kamgno","year":"2007","unstructured":"Kamgno J, Pion SD, Tejiokem MC, Twum-Danso NA, Thylefors B, Boussinesq M. Randomized, controlled, double-blind trial with ivermectin on Loa loa microfilaraemia: efficacy of a low dose (approximately 25 microg\/kg) versus current standard dose (150 microg\/kg). Trans R Soc Trop Med Hyg. 2007;101:777\u201385.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"7189_CR21","doi-asserted-by":"publisher","first-page":"379","DOI":"10.4269\/ajtmh.2010.09-0573","volume":"82","author":"J Kamgno","year":"2010","unstructured":"Kamgno J, Djomo PN, Pion SD, Thylefors B, Boussinesq M. A controlled trial to assess the effect of quinine, chloroquine, amodiaquine, and artesunate on Loa loa microfilaremia. Am J Trop Med Hyg. 2010;82:379\u201385.","journal-title":"Am J Trop Med Hyg"},{"key":"7189_CR22","doi-asserted-by":"publisher","first-page":"e0004492","DOI":"10.1371\/journal.pntd.0004492","volume":"10","author":"J Kamgno","year":"2016","unstructured":"Kamgno J, Nguipdop-Djomo P, Gounoue R, T\u00e9jiokem M, Kuesel AC. Effect of two or six doses 800 mg of albendazole every two months on Loa loa microfilaraemia: a double blind, randomized, placebo-controlled trial. PLoS Negl Trop Dis. 2016;10:e0004492.","journal-title":"PLoS Negl Trop Dis"},{"key":"7189_CR23","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/infdis\/168.1.202","volume":"168","author":"AD Klion","year":"1993","unstructured":"Klion AD, Massougbodji A, Horton J, Ekou\u00e9 S, Lanmasso T, Ahouissou NL, et al. Albendazole in human loiasis: results of a double-blind, placebo-controlled trial. J Infect Dis. 1993;168:202\u20136.","journal-title":"J Infect Dis"},{"key":"7189_CR24","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4269\/ajtmh.1998.58.458","volume":"58","author":"M Kombila","year":"1998","unstructured":"Kombila M, Duong TH, Ferrer A, Perret JL, Marion MC, Nguiri C, et al. Short- and long-term action of multiple doses of ivermectin on loiasis microfilaremia. Am J Trop Med Hyg. 1998;58:458\u201360.","journal-title":"Am J Trop Med Hyg"},{"key":"7189_CR25","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/0140-6736(93)92859-R","volume":"342","author":"Y Martin-Prevel","year":"1993","unstructured":"Martin-Prevel Y, Cosnefroy JY, Ngari P, Pinder M. Reduction of microfilaraemia with single high-dose of ivermectin in loiasis. Lancet. 1993;342:442.","journal-title":"Lancet"},{"key":"7189_CR26","doi-asserted-by":"publisher","first-page":"186","DOI":"10.4269\/ajtmh.1993.48.186","volume":"48","author":"Y Martin-Prevel","year":"1993","unstructured":"Martin-Prevel Y, Cosnefroy JY, Tshipamba P, Ngari P, Chodakewitz JA, Pinder M. Tolerance and efficacy of single high-dose ivermectin for the treatment of loiasis. Am J Trop Med Hyg. 1993;48:186\u201392.","journal-title":"Am J Trop Med Hyg"},{"key":"7189_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0140-6736(49)90994-0","volume":"2","author":"F Murgatroyd","year":"1949","unstructured":"Murgatroyd F, Woodruff AW. Loiasis treated with hetrazan. Lancet. 1949;2:147\u20139.","journal-title":"Lancet"},{"key":"7189_CR28","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3390\/pathogens9121043","volume":"9","author":"HC Nana-Djeunga","year":"2020","unstructured":"Nana-Djeunga HC, Lenou-Nanga CG, Donfo-Azafack C, Djune-Yemeli L, Fossuo-Thotchum F, Domche A, et al. Collateral impact of community-directed treatment with ivermectin (CDTI) for onchocerciasis on parasitological indicators of Loa loa infection. Pathogens. 2020;9:1043.","journal-title":"Pathogens"},{"key":"7189_CR29","unstructured":"O\u2019Connell E. Efficacy and microfilaricidal kinetics of imatinib for the treatment of Loa loa. Updated June 07, 2022. https:\/\/clinicaltrials.gov\/study\/NCT02644525?tab=results. Accessed 31 Jul 2024."},{"key":"7189_CR30","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0035-9203(96)90535-0","volume":"90","author":"S Ranque","year":"1996","unstructured":"Ranque S, Garcia A, Boussinesq M, Gardon J, Kamgno J, Chippaux JP. Decreased prevalence and intensity of Loa loa infection in a community treated with ivermectin every three months for two years. Trans R Soc Trop Med Hyg. 1996;90:429\u201330.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"7189_CR31","doi-asserted-by":"publisher","first-page":"480","DOI":"10.4269\/ajtmh.1988.39.480","volume":"39","author":"D Richard-Lenoble","year":"1988","unstructured":"Richard-Lenoble D, Kombila M, Rupp EA, Pappayliou ES, Gaxotte P, Nguiri C, et al. Ivermectin in loiasis and concomitant O. volvulus and M. perstans infections. Am J Trop Med Hyg. 1988;39:480\u20133.","journal-title":"Am J Trop Med Hyg"},{"key":"7189_CR32","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4269\/ajtmh.2004.71.211","volume":"71","author":"TE Tabi","year":"2004","unstructured":"Tabi TE, Befidi-Mengue R, Nutman TB, Horton J, Folefack A, Pensia E, et al. Human loiasis in a Cameroonian village: a double-blind, placebo-controlled, crossover clinical trial of a three-day albendazole regimen. Am J Trop Med Hyg. 2004;71:211\u20135.","journal-title":"Am J Trop Med Hyg"},{"key":"7189_CR33","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1179\/000349802125001933","volume":"96","author":"L Tsague-Dongmo","year":"2002","unstructured":"Tsague-Dongmo L, Kamgno J, Pion SD, Moyou-Somo R, Boussinesq M. Effects of a 3-day regimen of albendazole (800 mg daily) on Loa loa microfilaraemia. Ann Trop Med Parasitol. 2002;96:707\u201315.","journal-title":"Ann Trop Med Parasitol"},{"key":"7189_CR34","doi-asserted-by":"publisher","first-page":"e660","DOI":"10.1371\/journal.pntd.0000660","volume":"4","author":"JD Turner","year":"2010","unstructured":"Turner JD, Tendongfor N, Esum M, Johnston KL, Langley RS, Ford L, et al. Macrofilaricidal activity after doxycycline only treatment of Onchocerca volvulus in an area of Loa loa co-endemicity: a randomized controlled trial. PLoS Negl Trop Dis. 2010;4:e660.","journal-title":"PLoS Negl Trop Dis"},{"key":"7189_CR35","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1186\/1475-2883-2-S1-S7","volume":"2","author":"NA Twum-Danso","year":"2003","unstructured":"Twum-Danso NA. Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future. Filaria J. 2003;2:S7.","journal-title":"Filaria J"},{"key":"7189_CR36","doi-asserted-by":"publisher","first-page":"ofae240","DOI":"10.1093\/ofid\/ofae240","volume":"11","author":"GS Wafeu","year":"2024","unstructured":"Wafeu GS, Lepage TM, Campillo JT, Efon-Ekangouo A, Nana-Djeunga HC, Nzune-Toche N, et al. Safety and short-term efficacy of a single dose of 2\u2005mg moxidectin in Loa loa-infected individuals: a double-blind, randomized ivermectin-controlled trial with ascending microfilarial densities. Open Forum Infect Dis. 2024;11:ofae240.","journal-title":"Open Forum Infect Dis"},{"key":"7189_CR37","doi-asserted-by":"publisher","first-page":"e0011584","DOI":"10.1371\/journal.pntd.0011584","volume":"17","author":"R Zoleko-Manego","year":"2023","unstructured":"Zoleko-Manego R, Kreuzmair R, Veletzky L, Ndzebe-Ndoumba W, Ekoka Mbassi D, Okwu DG, et al. Efficacy, safety, and tolerability of albendazole and ivermectin based regimens for the treatment of microfilaraemic loiasis in adult patients in Gabon: a randomized controlled assessor blinded clinical trial. PLoS Negl Trop Dis. 2023;17:e0011584.","journal-title":"PLoS Negl Trop Dis"},{"key":"7189_CR38","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.3201\/eid2508.190011","volume":"25","author":"F Gobbi","year":"2019","unstructured":"Gobbi F, Buonfrate D, Tamarozzi F, Degani M, Angheben A, Bisoffi Z. Efficacy of high-dose albendazole with ivermectin for treating imported loiasis, Italy. Emerg Infect Dis. 2019;25:1574\u20136.","journal-title":"Emerg Infect Dis"},{"key":"7189_CR39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12879-019-4740-6","volume":"20","author":"O Bouchaud","year":"2020","unstructured":"Bouchaud O, Matheron S, Loarec A, Dupouy Camet J, Bour\u00e9e P, Godineau N, et al. Imported loiasis in France: a retrospective analysis of 167 cases with comparison between sub-Saharan and non sub-Saharan African patients. BMC Infect Dis. 2020;20:63.","journal-title":"BMC Infect Dis"},{"key":"7189_CR40","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.tmaid.2013.08.005","volume":"11","author":"N Gantois","year":"2013","unstructured":"Gantois N, Rapp C, Gautret P, Ficko C, Savini H, Larrech\u00e9 S, et al. Imported loiasis in France: a retrospective analysis of 47 cases. Travel Med Infect Dis. 2013;11:366\u201373.","journal-title":"Travel Med Infect Dis"},{"key":"7189_CR41","doi-asserted-by":"publisher","first-page":"e0006917","DOI":"10.1371\/journal.pntd.0006917","volume":"12","author":"F Gobbi","year":"2018","unstructured":"Gobbi F, Bottieau E, Bouchaud O, Buonfrate D, Salvador F, Rojo-Marcos G, et al. Comparison of different drug regimens for the treatment of loiasis-a TropNet retrospective study. PLoS Negl Trop Dis. 2018;12:e0006917.","journal-title":"PLoS Negl Trop Dis"},{"key":"7189_CR42","doi-asserted-by":"publisher","first-page":"ofz019","DOI":"10.1093\/ofid\/ofz019","volume":"6","author":"SD Pion","year":"2019","unstructured":"Pion SD, Tchatchueng-Mbougua JB, Chesnais CB, Kamgno J, Gardon J, Chippaux JP, et al. Effect of a single standard dose (150\u2013200 \u03bcg\/kg) of ivermectin on Loa loa microfilaremia: systematic review and meta-analysis. Open Forum Infect Dis. 2019;6:ofz019.","journal-title":"Open Forum Infect Dis"},{"key":"7189_CR43","doi-asserted-by":"publisher","first-page":"010413","DOI":"10.7189\/jogh.08.010413","volume":"8","author":"J Mischlinger","year":"2018","unstructured":"Mischlinger J, Veletzky L, Tazemda-Kuitsouc GB, Pitzinger P, Matsegui PB, Gmeiner M, et al. Behavioural and clinical predictors for loiasis. J Glob Health. 2018;8:010413.","journal-title":"J Glob Health"},{"key":"7189_CR44","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1097\/SCS.0000000000006429","volume":"31","author":"C McGuire","year":"2020","unstructured":"McGuire C, Samargandi OA, Boudreau C, Whelan A, Bezuhly M. Prevention of autologous costal cartilage graft warping in secondary rhinoplasty. J Craniofac Surg. 2020;31:1246\u201350.","journal-title":"J Craniofac Surg"},{"key":"7189_CR45","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/archdischild-2014-306953","volume":"101","author":"E de Vos-Kerkhof","year":"2016","unstructured":"de Vos-Kerkhof E, Geurts DH, Wiggers M, Moll HA, Oostenbrink R. Tools for \u201csafety netting\u201d in common paediatric illnesses: a systematic review in emergency care. Arch Dis Child. 2016;101:131\u20139.","journal-title":"Arch Dis Child"},{"key":"7189_CR46","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00423-024-03346-4","volume":"409","author":"H Santos-Sousa","year":"2024","unstructured":"Santos-Sousa H, Amorim-Cruz F, Nogueiro J, Silva A, Amorim-Cruz I, Ferreira-Santos R, et al. Preoperative risk factors for early postoperative bleeding after Roux-en-Y gastric bypass surgery: a systematic review and meta-analysis. Langenbecks Arch Surg. 2024;409:163.","journal-title":"Langenbecks Arch Surg"}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-025-07189-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13071-025-07189-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-025-07189-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T04:55:54Z","timestamp":1768366554000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13071-025-07189-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7189"],"URL":"https:\/\/doi.org\/10.1186\/s13071-025-07189-w","relation":{},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}